| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8750796 | Respiratory Investigation | 2017 | 6 Pages |
Abstract
Transitioning to riociguat may be safe and effective in CTEPH patients with inadequate clinical responses to PDE5i.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Keiko MD, Nobuhiro MD, PhD, FCCP, Rika MD, PhD, Akane MD, Akane MD, Ryogo MD, Hajime MD, PhD, Fumiaki MD, PhD, Ayumi MD, PhD, Rintaro MD, PhD, Takayuki MD, PhD, Toshihiko MD, PhD, Ayako MD, PhD, Seiichiro MD, PhD, Koichiro MD, PhD, FCCP,